Opna Bio Doses the First Patient with OPN-6602 in P-I Trial of Multiple Myeloma
Shots:
- Opna Bio has dosed the first patient with OPN-6602 under the P-I clinical evaluation for multiple myeloma
- The P-I study aims at evaluating the safety, tolerability, PK & preliminary anti-tumor activity of OPN-6602 alone & in addition to dexamethasone for treating r/r multiple myeloma patients (n=130) across the US, with anticipated completion date in H2’26
- OPN-6602 is an oral EP300/CBP inhibitor that reduces expression of IRF4 and MYC, key drivers of multiple myeloma. Its non-clinical results, highlighted at AACR 2024, demonstrated 71% tumor growth inhibition as a monotx. and >100% inhibition in combination trials
Related News:- Regeneron Showcases Updated on BLA for Linvoseltamab to Treat R/R Multiple Myeloma (MM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
